GenCurix Droplex POLE Study Published, Highlighting Endometrial Cancer Mutation Test

GenCurix, a precision medicine diagnostics company, said a study on its digital PCR (ddPCR)-based Droplex POLE Mutation Test for detecting POLE mutations in endometrial cancer has been published in an international journal. The test is a molecular diagnostic product designed to identify POLE mutations, drawing attention for its potential use in precision diagnosis of endometrial cancer. GenCurix has developed mutation detection tests based on digital PCR technology, and the publication is meaningful because the research results were introduced through an external academic channel. Attention now turns to whether the related technology can gain wider recognition in endometrial cancer diagnosis and precision medicine testing. Source: mk.co.kr